Skip to main content
. 2011 Nov 23;54(24):8328–8342. doi: 10.1021/jm2007326

Figure 4.

Figure 4

(A) Status of pS296 CHK1 autophosphorylation in SW620 tumor xenografts following treatment with either irinotecan alone or in combination with (R)-(3).(17) Tumor bearing animals were administered either vehicle alone, irinotecan alone (25 or 50 mg/kg ip), or irinotecan combined with a fixed dose of (R)-(3) (40 mg kg–1 ip) 1 h prior to irinotecan administration. Tumors were collected 6 or 24 h following treatment (6 or 24 after administration of the first agent for combinations) and snap frozen. Tumor protein expression was characterized by Western blotting using 50 μg of sample per lane. (B) Antitumor effects of combining (R)-3 with irinotecan in nude mice bearing SW620 xenograft tumors.(17) Symbols: (↑) dose administered; (■) vehicle alone; (shaded up triangles) irinotecan alone (12.5 mg/kg ip); (shaded down triangles) (R)-3 alone (40 mg/kg ip); (⧫) irinotecan and (R)-3 combined ((R)-3 dosed 1 h prior to and 24 h after irinotecan). Values are mean ± SEM; n = 9–11.